Announcement of amendment of the Company's 2021
Annual Report
Date of events
2022/08/11
To which item it meets
paragraph 50
Statement
1.Date of receipt of letter from TPEx to request
supplement or correction:2022/08/09
2.Deadline imposed for supplement or correction:2022/08/11
3.Content of supplement or correction:Pursuant to the instruction of Taipei
Exchange, the Company amend p4~6 and p12~13 of its Chinese version of
2021 Annual Report; p6~p8 and p20~22 of its English version of 2021 Annual
Report.
4.Countermeasures:Re-uploaded the Annual Report(Revised after the
Shareholder's Meeting) to MOPS.
5.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
OBI Pharma Inc. published this content on 11 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 August 2022 06:50:02 UTC.
OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.
OBI PHARMA, INC. 
